Comparing Two Brain Imaging Scans for Memory Loss Diagnosis
Tests a tau brain scan against an amyloid scan in people with mild memory problems.
Plain-language title generated from the registry record
Registry title: Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment
Key facts
- Where
- Geneva and Lausanne, SwitzerlandSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT06618872, who can take part
Where in Switzerland
- Geneva University HospitalGeneva, SwitzerlandTaking people
- Centre Medical Universitaire VaudoisLausanne, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Geneva
- Trial code
- NCT06618872
- Record updated
- 23 December 2025
- Original description
The objective of the study is to investigate the clinical validity of tau-PET with [18F]RO948 vs. amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementiaRead full original descriptionShow less
Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With
The objective of the study is to investigate the clinical validity of tau-PET with [18F]RO948 vs. amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementia
Inclusion: Written Inform Consent to participating; 50 to 85 years of age; a diagnosis of Mild Cognitive Impairment (MCI=at least one pathological neuropsychological test but no functional impairment based on the Amsterdam IADL score) or mild dementia (both cognitive and functional impairments); availability of MRI within 6 months before screening; prescription of a diagnostic amyloid PET; Willing and able to comply with the requirements of the study, as judged by the investigator.
Exclusion: Enrolment in previous clinical trials for AD potentially affecting amyloid and/or tau brain load; Ferromagnetic implants and devices (including implants or devices held in place by sutures, granulation or ingrowth of tissue, fixation devices, or by other means) not eligible for MRI scanning; The presence of psychiatric disorders, extensive white matter lesions or other stigmata of vascular dementia; Visual and auditory acuity inadequate for neuropsychological testing; Enrolment in other trials or studies not compatible with [18F]RO948 Imaging study; Women of childbearing potential must not be pregnant (negative urine β-hCG on the day of imaging) or breast feeding at screening.